sisonkestudy.samrc.ac.za
Open in
urlscan Pro
196.21.144.26
Public Scan
Submitted URL: http://sisonkestudy.samrc.ac.za/
Effective URL: https://sisonkestudy.samrc.ac.za/
Submission: On November 14 via api from US — Scanned from US
Effective URL: https://sisonkestudy.samrc.ac.za/
Submission: On November 14 via api from US — Scanned from US
Form analysis
1 forms found in the DOMPOST
<form id="contact" action="" method="post">
<div class="row">
<div class="col-md-12 col-sm-12">
<h2 style="color:white;">Contact us </h2>
<p> </p>
<h3 style="color:white;">Sisonke desk: 0800 014 956</h3>
<p> </p>
<p style="color:white;">
<font size="-1"><strong>Oversight ethics committee:</strong><br> South African Medical Research Council, Human Research Ethics Committee<br>
</font>
</p>
<p> </p>
<p style="color:white;">
<font size="-1"><strong>REGULATORY APPROVAL</strong><br> If you have questions about this study you should first discuss them with the Clinical Research Site team, or the Sisonke Safety Desk, or the related Ethics Committee. If you have not
been provided with answers to your satisfaction, you should write to the South African Health Products Regulatory Authority (SAHPRA) who provides regulatory approval for the study at: South African Health Products Regulatory Authority,
Department of Health, Private Bag X828; PRETORIA; 0001 </font>
</p>
</div>
</div>
</form>
Text Content
* Home * About * Eligibility * SHERPA Resources * Sisonke Study 1 * Sisonke Study 2 * Contact Us Menu SISONKE STUDY Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S Find Out More ABOUT SHERPA Short for Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S, the SHERPA Study’s primary objective is to evaluate the effectiveness of the heterologous mRNA-1273 (Moderna) boost against COVID-19 infections and severe COVID-19 disease among health care workers. The study aims to enroll up to 15 000 Sisonke participants who have received either a single or two doses of Ad26.COV2.S. This will allow the study team to investigate the effectiveness of the Moderna COVID-19 vaccine booster against the new variants in South Africa, as well as provide the South African Health Products Regulatory Authority (SAHPRA) with additional data on this vaccine for potential licensing. ELIGIBILITY Who can enroll? * • Anyone who has received either a single or two doses of Ad26.COV2.S through the Sisonke study and you are 18 years or older * • If you are pregnant or breastfeeding at the time of enrolment you can join the study. * • You must be willing and able to comply with the vaccination plan and other study procedures. * • You must be capable and willing to provide informed consent You may NOT enrol * • If you have received any COVID-19 vaccines other than one or two doses of Ad26.CoV2.S through other means (for example, another mRNA booster dose). * • If you are currently participating in any other research studies (other than Sisonke) that would interfere with the objectives of this study. * • If you have had COVID-19 or a COVID-19 illness within 14 days of enrolment * • If you have a history of heparin-induced thrombocytopenia, or thrombosis and thrombocytopenia syndrome. * • If you have a history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of mRNA-1273. How to enroll? Contact your nearest SHERPA site if you receive the SMS about the SHERPA study or click on the link https://redcap.link/sherpa SOUTH AFRICAN MEDICAL RESEARCH COUNCIL Building a healthy nation through research, innovation and transformation Read more CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA Generating Knowledge - Impacting Health Read More DESMOND TUTU HEALTH FOUNDATION Lessen the impact of the HIV epidemic on individuals, families and communities Read More MODERNA Pioneering mRNA technology Read More SOUTH AFRICAN MEDICAL RESEARCH COUNCIL Building a healthy nation through research, innovation and transformation Read more CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA Generating Knowledge - Impacting Health Read More DESMOND TUTU HEALTH FOUNDATION Lessen the impact of the HIV epidemic on individuals, families and communities Read More MODERNA Pioneering mRNA technology Read More SOUTH AFRICAN MEDICAL RESEARCH COUNCIL Building a healthy nation through research, innovation and transformation Read more CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA Generating Knowledge - Impacting Health Read More ‹› SHERPA RESOURCES PRESS RELEASES SAMRC launches a study to evaluate the effectiveness of the Moderna booster, 1 June 2022 INFORMATION • Participants Information and Consent Form - An example of an information sheet and consent form. (Please note that the information and consent process will occur at each clinical research site) • SHERPA study Frequently Asked Questions • Participant letter - 7 Oct 2022 CONTACT US SISONKE DESK: 0800 014 956 Oversight ethics committee: South African Medical Research Council, Human Research Ethics Committee REGULATORY APPROVAL If you have questions about this study you should first discuss them with the Clinical Research Site team, or the Sisonke Safety Desk, or the related Ethics Committee. If you have not been provided with answers to your satisfaction, you should write to the South African Health Products Regulatory Authority (SAHPRA) who provides regulatory approval for the study at: South African Health Products Regulatory Authority, Department of Health, Private Bag X828; PRETORIA; 0001 Copyright © 2022 Sisonke. Hosted by the: South African Medical Research Council * * * * *